GlassScriptPhysician profile
Joseph V Vandergriff
NPI 1659474658
$6,349.45
in general payments reported to CMS, 2019-2025
32 companies · $443 in 2025
The $443 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,144 · 2020: $1,033 · 2021: $1,470 · 2022: $1,028 · 2023: $715 · 2024: $517 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,675.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $961.99 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Lilly USA, LLC | $658.16 | 2019-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $647.89 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $569.74 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $569.66 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $505.33 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $416.44 | 2019-2022 | |
| Glaxosmithkline, LLC. | $357.62 | 2020-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $306.16 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $249.38 | 2019-2023 | Steglatro, Steglujan, Segluromet |
| Amarin Pharma, INC. | $238.69 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $155.89 | 2019-2020 | |
| Amgen INC. | $104.37 | 2019-2024 | Krystexxa, Otezla, Repatha |
| Hologic Sales and Service, LLC | $64.75 | 2023-2024 | Aptima, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $58.64 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $55.02 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.03 | 2025 | Caplyta |
| Genentech USA, INC. | $39.11 | 2019-2020 | |
| Antares Pharma, INC. | $36.67 | 2021 | |
| Eisai INC. | $33.79 | 2022 | |
| Neos Therapeutics, LP | $30.76 | 2021 | |
| Horizon Therapeutics Plc | $30.41 | 2019-2022 | |
| Inari Medical, INC. | $28.89 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Takeda Pharmaceuticals U.S.A., INC. | $28.79 | 2020 | |
| Recor Medical INC | $25.77 | 2025 | Paradise Ultrasound Renal Denervation System |
| E.R. Squibb & Sons, L.L.C. | $23.93 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $21.71 | 2021 | |
| Exact Sciences Corporation | $20.74 | 2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $18.99 | 2023 | |
| Corcept Therapeutics | $17.69 | 2025 | Korlym |
| Boston Scientific Corporation | $14.11 | 2020 | |
| Shire North American Group INC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Vandergriff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.